Servier - Articles and news items

First patient treated in Phase I UCART19 trial in paediatric B-ALL

Industry news / 21 June 2016 / Victoria White, Digital Content Producer

The Phase I study will evaluate the ability of UCART19 to induce molecular remission in paediatric patients with relapsed or refractory CD19 positive B-ALL…

EC grants marketing authorisation to Lonsurf in mCRC

Industry news / 27 April 2016 / Victoria White, Digital Content Producer

The decision from the EC was based on data from the international, double-blind, placebo-controlled Phase III RECOURSE study…

Servier exercises options to acquire worldwide rights to UCART19

Industry news / 19 November 2015 / Victoria White

Earlier this month, Great Ormond Street Hospital (GOSH) reported that UCART19 had been used treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia…

Amgen logo

Amgen and Servier complete product collaboration transaction

Industry news, News / 12 August 2013 / Amgen

Amgen and Servier announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement…

Amgen logo

Amgen and Servier announce product collaboration

Industry news, News / 9 July 2013 / Amgen

Amgen obtains US rights to novel EU-approved cardiovascular therapy; Servier receives option for omecamtiv mecarbil in Europe…

Boehringer Ingelheim logo

Boehringer Ingelheim Biopharmaceuticals announces manufacturing agreement with Servier

Industry news, News / 3 August 2012 / Boehringer Ingelheim

Boehringer Ingelheim announced an agreement with Servier & its partner XOMA Corporation…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...